Ulcerative Colitis
Conditions
Interventions
Patients in the treatment group receive an antibiotic combination consisting of amoxicillin 500mg tid, tetracycline 500mg tid, and metronidazole 250mg tid for two weeks.
patients in the control group
Sponsors
Japan UC Antibiotics-therapy Study Group(JUCASG)
Nihon University,Iwate Medical University, Kyoto Central Hospital Yamagata Central Hospital Oita University, Tokyo Medical University Toyama Medical & Pharmaceutical University, Showa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: chronic relapsing and refractory ulcerative colitis patients who have inflammatory colonic mucosa and who attend regular outpatient or inpatient clinics at the Department of Gastroenterology
Exclusion criteria
Exclusion criteria: Patients are excluded if they have toxic megacolon, if they have allergy to penicillin, if they are pregnant, if they have serious liver or renal disease or if they have psychological disease. In addition, patients who have taken antibiotics within four weeks of study entry and have Clostridium difficle or other stool pathogens at entry are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| symptom assessment, endoscopic and histological evaluations, laboratory findings | — |
Secondary
| Measure | Time frame |
|---|---|
| the titers of antibody to F. varium and the F. varium density in the mucosa | — |
Countries
Japan
Contacts
Public ContactToshifumi Ohkusa
Juntendo University School of Medicine Department of Gastroenterology
Outcome results
None listed